Clinical trials: Nephrotic Syndrome
Crohn's Disease, Nephrotic Syndrome
Glucocorticoid-induced Osteopenia in Children
The purpose of this study is to characterize the skeletal deficits and risk factors for impaired skeletal development in children requiring glucocorticoid therapy.
- Trial name
- NCT00289328
- Where
- United States
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Minimal Change Disease, Focal Segmental Glomerulosclerosis
Efficacy and Safety of VB119 in Subjects With Minimal Change Disease (MCD) and Focal Segmental Glomerulosclerosis (FSGS)
Phase 2, multi-center, proof-of-concept study to evaluate the safety and efficacy of VB119 on the maintenance of remission and duration of response in adults with primary MCD or primary FSGS who previously responded to steroid…
- Trial name
- NCT05441826
- Testing
- VB119
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Tenet Medicines
Steroid-Resistant Nephrotic Syndrome
ACTHAR Gel for Drug REsistant Nephrotic Syndrome in Children
We propose to study the use of purified porcine Acthar Gel (ACTHAR, Mallinckrodt Pharmaceuticals) for treatment of steroid resistance nephrotic syndrome (SRNS) in a prospective pilot study.
- Trial name
- ADRENL (NCT03408405)
- Testing
- Acthar Gel 80 UNT/ML Injectable Solution
- Sponsor
- Rhode Island Hospital
Nephrotic Syndrome, Hypoalbuminemia
Edoxaban Steady-State PK/PD in Adults With Nephrotic Syndrome
A study to evaluate the impact of nephrotic syndrome on the steady state pharmacokinetics and pharmacodynamics of edoxaban compared to health volunteers, and whether edoxaban can provide an equivalent anticoagulant effect to…
- Trial name
- NCT07116239
- Testing
- Edoxaban 60 mg, Enoxaparin 40 mg
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Peking University People's Hospital
Focal Segmental Glomerulosclerosis, Minimal Change Disease
An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Podocyte Diseases
Background: Podocyte diseases are a group of kidney conditions that include focal segmental glomerulosclerosis (FSGS), minimal change disease (MCD), and membranous nephropathy (MN).
- Conditions
- Focal Segmental Glomerulosclerosis, Minimal Change Disease, Membranous Nephropathy
- Trial name
- NCT06664814
- Testing
- ManNAc
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Human Genome Research Institute (NHGRI)
Glomerulosclerosis, Focal Segmental, Minimal Change Disease
A Study to Understand the Genetics and Clinical Course of Focal Segmental Glomerulosclerosis (FSGS), Treatment-Resistant Minimal Change Disease (TR-MCD), and Diabetic Nephropathy (DN)
This is a study with 2 parts. Part 1 comprises a visit to collect biological samples necessary for the molecular characterization of chronic kidney disease.
- Conditions
- Glomerulosclerosis, Focal Segmental, Minimal Change Disease, Diabetic Nephropathies
- Trial name
- NCT04235621
- Testing
- FSGS/TR-MCD, Diabetic Nephropathy (DN)
- Where
- 18 sites in United States
- Volunteers
- 20 people
- Sponsor
- Goldfinch Bio, Inc.
Sphingosine Phosphate Lyase Insufficiency Syndrome (SPLIS)
Natural History of Sphingosine Phosphate Lyase Insufficiency Syndrome (SPLIS)
This is a prospective longitudinal natural history study with a retrospective cross-sectional arm aimed at determining the natural history of sphingosine phosphate lyase insufficiency syndrome (SPLIS), a recently recognized…
- Trial name
- SPLIS-HIS (NCT06669949)
- Testing
- no intervention
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of California, San Francisco
Nephrotic Syndrome, Sodium-Glucose Transporter 2 Inhibitors
Clinical Value of Adding Dapagliflozin in Patients With Nephrotic Syndrome
Conducted as a randomized controlled clinical trial, this study aims to assess the potential benefits of incorporating dapagliflozin, an SGLT-2 inhibitor, into the treatment regimen of patients diagnosed with primary nephrotic…
- Trial name
- NCT06026787
- Testing
- Dapagliflozin 10mg Tab
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Ain Shams University
Nephrotic Syndrome in Children
Study of Tacrolimus vs Mycophenolate Mofetil in Pediatric Patients With Nephrotic Syndrome
Primary nephrotic syndrome accounts for approximately 90% of the total number of nephrotic syndrome in childhood and it is the most common glomerular disease in children.
- Trial name
- STAMP (NCT04048161)
- Testing
- Tacrolimus, Mycophenolate Mofetil
- Where
- 12 sites in China
- Volunteers
- 270 people
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine
Idiopathic Nephrotic Syndrome
Factors of Steroid Dependency in Idiopathic Nephrotic Syndrome
The primary purpose of the study is to identify the factors of steroid dependency in childhood idiopathic nephrotic syndrome. The steroid dependency is defined by a relapse of nephrotic syndrome within the 3 weeks that follow the…
- Trial name
- NEPHROVIR-2 (NCT01609426)
- Testing
- DNA chip dedicated to the pharmacogenetic of steroids
- Where
- France
- Volunteers
- 351 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Membranous Glomerulonephritis, Lupus Membranous Nepropathy
Sirolimus Therapy for Idiopathic and Lupus Membranous Nephropathy
This study will evaluate the safety and effectiveness of a new immunosuppressive drug, sirolimus, in reducing the amount of protein in the urine in patients with membranous nephropathy.
- Trial name
- NCT00050713
- Testing
- Sirolimus
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Primary Focal Segmental Glomerulosclerosis
FIRSTx - A Study of Oral CXA-10 in Primary Focal Segmental Glomerulosclerosis (FSGS)
This is a multicenter, open label, randomized study investigating two dose titration regimens of CXA-10 in subjects at least 18 years of age with primary FSGS.
- Trial name
- NCT03422510
- Testing
- CXA-10
- Where
- 24 sites in United States
- Volunteers
- 33 people
- Sponsor
- Complexa, Inc.
Nephrotic Syndrome in Children
Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil in Children With Steroid-dependent Nephrotic Syndrome
The goal of this clinical trial is to evaluate the efficacy and safety of rituximab(RTX) and mycophenolate mofetile(MMF) in the treatment of children with low-dose steroid-dependent nephrotic syndrome(SDNS).
- Trial name
- NCT05843968
- Testing
- Rituximab, Mycophenolate Mofetil
- Where
- China
- Volunteers
- 46 people
- Sponsor
- Children's Hospital of Chongqing Medical University
Nephrotic Syndrome
Efficacy and Safety of Rituximab to That of Calcineurin Inhibitors in Children With Steroid Dependent Nephrotic Syndrome
Nephrotic syndrome in children is primarily caused by minimal change disease. Majority of these patients respond well to corticosteroids.
- Trial name
- NCT02438982
- Testing
- Tacrolimus, Rituximab
- Where
- India
- Volunteers
- 120 people
- Sponsor
- Nilratan Sircar Medical College
Steroid-Dependent Nephrotic Syndrome, Steroid-Sensitive Nephrotic Syndrome
Efficacy and Safety of Obinutuzumab Versus Rituximab in Childhood Steroid Dependant and Frequent Relapsing Nephrotic Syndrome
B-cell depletion with rituximab induces sustained remission in children with Steroid-Dependent or Frequent Relapsing Nephrotic Syndrome (SD/FRNS).
- Trial name
- OBIRINS (NCT05786768)
- Testing
- single infusion of Rituximab, single infusion of Obinutuzumab
- Where
- France
- Volunteers
- 88 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Nephrotic Syndrome, Edema
Role of Acetazolamide and Hydrochlorothiazide Followed by Furosemide in Treating Nephrotic Edema
The purpose of this study is to determine whether using furosemide following acetazolamide is effective in treating refractory edema associated with nephrotic syndrome.
- Trial name
- NCT02427880
- Testing
- Acetazolamide and Hydrochlorothiazide Followed by Furosemide, Furosemide and Hydrochlorothiazide Followed by Furosemide
- Volunteers
- 20 people
- Sponsor
- Shiraz University of Medical Sciences
Nephrotic Syndrome
Effect of Dapagliflozin in Non-Diabetic Patients With Nephrotic Syndrome.
Dapagliflozin is the first SGLT2 inhibitor to be approved for CKD treatment regardless of diabetes status. Since many etiologies of non-diabetic nephropathy are characterized by intraglomerular hypertension, it was hypothesized…
- Trial name
- NCT05966818
- Testing
- Dapagliflozin and Standard therapy (ACEI or ARB)., Standard Therapy (ACEI or ARB).
- Volunteers
- 90 people
- Sponsor
- Ain Shams University
Nephrotic Syndrome in Children, Nephrotic Syndrome, Minimal Change
REduced-dose Steroid PrOtocol for Childhood Nephrotic SyndromE (RESPONSE)
This is a pilot feasibility study for a proposed full-scale randomized controlled trial to evaluate the effectiveness and safety of a reduced-dose oral prednisone (steroids) regimen to treat childhood steroid-sensitive nephrotic…
- Conditions
- Nephrotic Syndrome in Children, Nephrotic Syndrome, Minimal Change, Nephrotic Syndrome, Nephrotic Syndrome，Idiopathic
- Trial name
- RESPONSE (NCT06635720)
- Testing
- Prednisone
- Where
- Canada
- Volunteers
- 50 people
- Sponsor
- The Hospital for Sick Children
First Manifestation of Steroid Sensitive Nephrotic Syndrome
Efficiency of Levamisole for Maintaining Remission After the First Flare of Steroid Sensitive Nephrotic Syndrome in Children
Idiopathic Nephrotic Syndrome is sensitive to steroid in 90% of children. However, most patients relapse and become steroid-dependant, with a long lasting relapsing course.
- Trial name
- NEPHROVIR3 (NCT02818738)
- Testing
- Levamisole Hydrochloride
- Where
- France
- Volunteers
- 86 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Focal Segmental Glomerulosclerosis
A Study of CCX140-B in Subjects With Primary FSGS and Nephrotic Syndrome
An Open Label, Intra-Subject Dose Escalation Study of CCX140 B in Subjects with Primary FSGS and Nephrotic Syndrome
- Trial name
- NCT03703908
- Testing
- CCX140-B
- Where
- 5 sites in United States
- Volunteers
- 5 people
- Sponsor
- Amgen